Steve E. Krognes - 19 Aug 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
19 Aug 2021
Net transactions value
-$113,263
Form type
4
Filing time
23 Aug 2021, 20:24:34 UTC
Previous filing
19 Nov 2021
Next filing
05 Jan 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $103,249 -2,085 -2.1% $49.52 95,502 19 Aug 2021 Direct F1, F2, F3
transaction DNLI Common Stock Sale $10,014 -200 -0.21% $50.07 95,302 19 Aug 2021 Direct F1, F3, F4
holding DNLI Common Stock 850,000 19 Aug 2021 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $49.00 to $49.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 75,358 restricted stock units.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $50.04 to $50.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.